A health condition that exists alongside a primary condition, for example type 2 diabetes, high blood pressure, or sleep apnea occurring with obesity.
Updated Sep 26, 2026
A comorbidity is a health condition that exists alongside another condition. In the GLP-1 context it usually means a condition occurring together with overweight or obesity, such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or heart disease.
Comorbidities matter practically in two ways. Clinically, they shape treatment decisions: many weight-management medication labels set a lower BMI threshold when at least one weight-related comorbidity is present. The trials behind the Zepbound label ↗ (external link), for example, enrolled adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition. And for coverage, insurers frequently require a documented comorbidity before approving a GLP-1 for weight management, which is why the term shows up so often in prior-authorization and appeal paperwork.
comorbiditydiagnosisinsuranceeligibility
Was this helpful?
Revision history
Last updated · 2 revisions recorded.
Show what changed
v2
Summary rewritten; Body revised; Metadata updated
v1
Existing article recorded at the start of version history
Improve this page▾
Community notes
Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.
Loading notes…
New submissions are currently paused. Existing approved notes remain available.
Related terms
Hazard ratio — A statistic from clinical trials that compares how often an event happens over time in one group versus another; below 1 means a lower rate in the treated group.
Sharps container — A puncture-resistant container for safely collecting used needles, pen needles, and syringes until they can be disposed of according to local rules.
Related guides
What obesity actually is: history, diagnosis, and why medicine calls it a chronic disease — The formula used to diagnose obesity was invented in the 1830s by an astronomer studying populations, not patients, and a lot of what we assume about obesity rests on tools and ideas never designed for the job. How the definition moved from moral failing to medical diagnosis, how it's diagnosed today, why major medical bodies classify it as a disease, why it's considered chronic, and where the stigma comes from.
Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis — GLP-1 medications slow the stomach, but the trials show the effect is smaller and fades more than most people assume, especially with the long-acting weekly drugs. This guide covers how much slower, whether it lasts, how gastric emptying is measured, how it differs from gastroparesis, and why the "food ferments in your stomach" claim has no evidence behind it.
Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration — Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo — There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.